The effect of cyclophosphamide on the immune system: implications for clinical cancer therapy

Cancer Chemotherapy and Pharmacology

Volumn 78, Issue 4, 2016, Pages 661-671

  Ahlmann, Martina ^a   Hempel, Georg ^b  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Immune reactivation; Immunosuppression; Oxazaphosphorines; T cells

Indexed keywords

ADENOSINE TRIPHOSPHATE; ALDEHYDE DEHYDROGENASE ISOENZYME 1; CYCLOPHOSPHAMIDE; HORMONE RECEPTOR; INDOLEAMINE 2,3 DIOXYGENASE; MULTIDRUG RESISTANCE PROTEIN 1; ALKYLATING AGENT; IMMUNOLOGIC FACTOR; IMMUNOSUPPRESSIVE AGENT;

ADVANCED CANCER; CANCER IMMUNIZATION; CANCER THERAPY; DRUG EFFECT; DRUG MECHANISM; DRUG METABOLISM; HEMATOPOIETIC CELL; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; MICROBIOME; NONHUMAN; PHARMACOGENETICS; PRIORITY JOURNAL; REVIEW; SUPPRESSOR CELL; T LYMPHOCYTE; IMMUNE SYSTEM; IMMUNOLOGY; NEOPLASM;

ANTINEOPLASTIC AGENTS, ALKYLATING; CYCLOPHOSPHAMIDE; HUMANS; IMMUNE SYSTEM; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; NEOPLASMS;

EID: 84988416305     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-016-3152-1     Document Type: Review

References (83)

1. Brock N, Wilmanns H (1958) Effect of a cyclic nitrogen mustard-phosphamidester on experimentally induced tumors in rats; chemotherapeutic effect and pharmacological properties of B518 ASTA [German]. Dtsch Med Wochenschr 83:453–458
2. Emadi A, Jones RJ, Brodsky RA (2009) Cyclophosphamide and cancer: golden anniversary. Nat Rev Clin Oncol 6:638–647
3. Baxter Oncology. German Product Summary Endoxan®. http://www.fachinfo.de/suche/fi/000728. Accessed Jan 2015
4. Santos GW, Sensenbrenner LL, Burke PJ, Mullins GM, Blas WB, Tutschka PJ, Slavin RE (1972) The use of cyclophosphamide for clinical marrow transplantation. Transpl Proc 4:559–564
5. Wang JY, Prorok G, Vaughan WP (1993) Cytotoxicity, DNA cross-linking, and DNA single-strand breaks induced by cyclophosphamide in a rat leukemia in vivo. Cancer Chemother Pharmacol 31:381–386
6. Fleer R, Brendel M (1981) Toxicity, interstrand cross-links and DNA fragmentation induced by ‘activated’ cyclophosphamide in yeast. Chem Biol Interact 37:123–140
7. Van Putten LM, Lelieveld P, Kram-Idsenga LKJ (1972) Cell-cycle specificity and therapeutic effectiveness of cytostatic agents. Cancer Chemother Rep 56:691–700
8. Candeias SM, Gaipl US (2016) The immune system in cancer prevention, development and therapy. Anticancer Agents Med Chem 16:101–107
9. Postow MA, Callahan MK, Wolchok JD (2015) Immune checkpoint blockade in cancer therapy. J Clin Oncol 33:1974–1982
10. Tsung K, Norton JA (2015) An immunological view of chemotherapy. Immunotherapy. 7:941–943
11. Yule SM, Boddy AV, Cole M, Price L, Wyllie R, Tasso MJ, Pearson AD, Idle JR (1995) Cyclophosphamide metabolism in children. Cancer Res 55:803–809
12. Bohnenstengel F, Hofmann U, Eichelbaum M, Kroemer HK (1996) Characterization of the cytochrome P450 involved in side-chain oxidation of cyclophosphamide in humans. Eur J Clin Pharmacol 51:297–301
13. Brüggemann SK, Kisro J, Wagner T (1997) Ifosfamide cytotoxicity on human tumor and renal cells: role of chloroacetaldehyde in comparison to 4-hydroxyifosfamide. Cancer Res 57:2676–2680
14. Sood C, O’Brien PJ (1996) 2-Chloroacetaldehyde-induced cerebral glutathione depletion and neurotoxicity. Br J Cancer Suppl 27:S287–S293
15. Audemard-Verger A, Martin Silva N, Verstuyft C, Costedoat-Chalumeau N, Hummel A, Le Guern V, Sacré K, Meyer O, Daugas E, Goujard C, Sultan A, Lobbedez T, Galicier L, Pourrat J, Le Hello C, Godin M, Morello R, Lambert M, Hachulla E, Vanhille P, Queffeulou G, Potier J, Dion JJ, Bataille P, Chauveau D, Moulis G, Farge-Bancel D, Duhaut P, Saint-Marcoux B, Deroux A, Manuzak J, Francès C, Aumaitre O, Bezanahary H, Becquemont L, Bienvenu B (2016) Glutathione S transferases polymorphisms are independent prognostic factors in lupus nephritis treated with cyclophosphamide. PLoS One 11:e0151696. doi:10.1371/journal.pone.0151696
16. de Jonge ME, Huitema AD, Rodenhuis S, Beijnen JH (2005) Clinical pharmacokinetics of cyclophosphamide. Clin Pharmacokinet 44:1135–1164
17. Yule SM, Price L, Cole M, Pearson AD, Boddy AV (2001) Cyclophosphamide metabolism in children following a 1-h and a 24-h infusion. Cancer Chemother Pharmacol 47:222–228
18. Svensson HM, Ljungman P, Björkstrand B, Olsson H, Bielenstein M, Abdel-Rehim M, Nilsson C, Johansson M, Karlsson MO (1999) A mechanism-based pharmacokinetic-enzyme model for cyclophosphamide autoinduction in breast cancer patients. Br J Clin Pharmacol 48:669–677
19. McCune JS, Batchelder A, Guthrie KA, Witherspoon R, Appelbaum FR, Phillips B, Vicini P, Salinger DH, McDonald GB (2009) Personalized dosing of cyclophosphamide in the total body irradiation-cyclophosphamide conditioning regimen: a phase II trial in patients with hematologic malignancy. Clin Pharmacol Ther 85:615–622
20. Hipkens JH, Struck RF, Gurtoo HL (1981) Role of aldehyde dehydrogenase in the metabolism-dependent biological activity of cyclophosphamide. Cancer Res 41:3571–3583
21. Jones RJ, Barber JP, Vala MS, Collector MI, Kaufmann SH, Ludeman SM, Colvin OM, Hilton J (1995) Assessment of aldehyde dehydrogenase in viable cells. Blood 85:2742–2746
22. Pinto N, Ludeman SM, Dolan ME (2009) Drug focus: pharmacogenetic studies related to cyclophosphamide-based therapy. Pharmacogenomics 10:1897–1903
23. Zhong S, Huang M, Yang X, Liang L, Wang Y, Romkes M, Duan W, Chan E, Zhou SF (2006) Relationship of glutathione S-transferase genotypes with side-effects of pulsed cyclophosphamide therapy in patients with systemic lupus erythematosus. Br J Clin Pharmacol 62:457–472
24. Penel N, Adenis A, Bocci G (2012) Cyclophosphamide-based metronomic chemotherapy: after 10 years of experience, where do we stand and where are we going? Crit Rev Oncol Hematol 82:40–50
25. Potel J, Brock N (1965) The influence of anticarcinogenic substances on immunologic reactions. 2. The influence of N, N-bis-(2-chlorethyl)-N’, O-propylenephosphoric acid ester diamide on antibody formation. Arzneimittelforschung 15:659–666
26. Müller US, Wirth W, Junge-Hülsing G, Hauss WH (1973) Suppressive effects in mesenchyme and immunosuppressive effects of cytostatics. Int J Clin Pharmacol 7:228–233
27. Potel J (1969) Immunsuppression durch kanzerotoxische Substanzen. Organtransplantation Immunologie und Klinik. F.K.Schattauer Verlag Stuttgart
28. Müller US, Wirth W, Thöne F, Junge-Hülsing G, Hauss WH (1973) Animal experiments on the anti-inflammatory and immunosuppressive effect of cytostatic agents. Arzneimittelforschung 23:487–491
29. Brock N, Kuhlmann J (1974) Pharmacological studies with alkylsulfonyloxyalkyl substituted and chloroethyl substituted oxazaphosphorine-2-oxides. 1. Communication: relationship between chemical structure and pharmacological action. Arzneimittelforschung 24:1139–1149
30. Polak L, Turk JL (1974) Reversal of immunological tolerance by cyclophosphamide through inhibition of suppressor cell activity. Nature 249:654–656
31. Röllinghoff M, Starzinski-Powitz A, Pfizenmaier K, Wagner H (1977) Cyclophosphamide-sensitive T lymphocytes suppress the in vivo generation of antigen-specific cytotoxic T lymphocytes. J Exp Med 145:455–459
32. Awwad M, North RJ (1988) Cyclophosphamide (Cy)-facilitated adoptive immunotherapy of a Cy-resistant tumour. Evidence that Cy permits the expression of adoptive T-cell mediated immunity by removing suppressor T cells rather than by reducing tumour burden. Immunology 65:87–92
33. Le DT, Jaffee EM (2012) Regulatory T-cell modulation using cyclophosphamide in vaccine approaches: a current perspective. Cancer Res 72:3439–3444
34. Liu Z, Huang Q, Liu G, Dang L, Chu D, Tao K, Wang W (2014) Presence of FoxP3(+)Treg cells is correlated with colorectal cancer progression. Int J Clin Exp Med 7:1781–1785
35. regs to neoadjuvant chemotherapy associated with favorable prognosis in advanced gastric cancer. Onco Targets Therapy 9:3525–3533
36. Engels CC, Charehbili A, van de Velde CJ, Bastiaannet E, Sajet A, Putter H, van Vliet EA, van Vlierberghe RL, Smit VT, Bartlett JM, Seynaeve C, Liefers GJ, Kuppen PJ (2015) The prognostic and predictive value of Tregs and tumor immune subtypes in postmenopausal, hormone receptor-positive breast cancer patients treated with adjuvant endocrine therapy: a Dutch TEAM study analysis. Breast Cancer Res Treat 149:587–596
37. Anderson BJ, Holford N (2008) Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol 48:303–332
38. Peng S, Lyford-Pike S, Akpeng B, Wu A, Hung CF, Hannaman D, Saunders JR, Wu TC, Pai SI (2013) Low-dose cyclophosphamide administered as daily or single dose enhances the antitumor effects of a therapeutic HPV vaccine. Cancer Immunol Immunother 62:171–182
39. Son CH, Shin DY, Kim SD, Park HS, Jung MH, Bae JH, Kang CD, Yang K, Park YS (2012) Improvement of antitumor effect of intratumoral injection of immature dendritic cells into irradiated tumor by cyclophosphamide in mouse colon cancer model. J Immunother 35:607–614
40. Tongu M, Harashima N, Yamada T, Harada T, Harada M (2010) Immunogenic chemotherapy with cyclophosphamide and doxorubicin against established murine carcinoma. Cancer Immunol Immunother 59:769–777
41. Salem ML, Kadima AN, El-Naggar SA, Rubinstein MP, Chen Y, Gillanders WE, Cole DJ (2007) Defining the ability of cyclophosphamide preconditioning to enhance the antigen-specific CD8+ T-cell response to peptide vaccination: creation of a beneficial host microenvironment involving type I IFNs and myeloid cells. J Immunother 30:40–53
42. Salem ML, Al-Khami AA, El-Naggar SA, Díaz-Montero CM, Chen Y, Cole DJ (2010) Cyclophosphamide induces dynamic alterations in the host microenvironments resulting in a Flt3 ligand-dependent expansion of dendritic cells. J Immunol 184:1737–1747
43. Angulo I, de las Heras FG, García-Bustos JF, Gargallo D, Muñoz-Fernández MA, Fresno M (2000) Nitric oxide-producing CD11b(+)Ly-6G(Gr-1)(+)CD31(ER-MP12)(+) cells in the spleen of cyclophosphamide-treated mice: implications for T-cell responses in immunosuppressed mice. Blood 95:212–220
44. Suzuki E, Kapoor V, Jassar AS, Kaiser LR, Albelda SM (2005) Gemcitabine selectively eliminate splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhance antitumor immune activity. Clin Cancer Res 11:6713–6721
45. Tongu M, Harashima N, Monma H, Inao T, Yamada T, Kawauchi H, Harada M (2013) Metronomic chemotherapy with low-dose cyclophosphamide plus gemcitabine can induce anti-tumor T cell immunity in vivo. Cancer Immunol Immunother 62:383–391
46. Cao Y, Zhao J, Yang Z, Cai Z, Zhang B, Zhou Y, Shen GX, Chen X, Li S, Huang B (2010) CD4+ FOXP3+ regulatory T cell depletion by low-dose cyclophosphamide prevents recurrence in patients with large condylomata acuminata after laser therapy. Clin Immunol 136:21–29
47. Ge Y, Domschke C, Stoiber N, Schott S, Heil J, Rom J, Blumenstein M, Thum J, Sohn C, Schneeweiss A, Beckhove P, Schuetz F (2012) Metronomic cyclophosphamide treatment in metastasized breast cancer patients: immunological effects and clinical outcome. Cancer Immunol Immunother 61:353–362
48. Ellebaek E, Engell-Noerregaard L, Iversen TZ, Froesig TM, Munir S, Hadrup SR, Andersen MH (2012) Svane IM metastatic melanoma patients treated with dendritic cell vaccination, interleukin-2 and metronomic cyclophosphamide: results from a phase II trial. Cancer Immunol Immunother 61:1791–1804
49. Walter S, Weinschenk T, Stenzl A, Zdrojowy R, Pluzanska A, Szczylik C, Staehler M, Brugger W, Dietrich PY, Mendrzyk R, Hilf N, Schoor O, Fritsche J, Mahr A, Maurer D, Vass V, Trautwein C, Lewandrowski P, Flohr C, Pohla H, Stanczak JJ, Bronte V, Mandruzzato S, Biedermann T, Pawelec G, Derhovanessian E, Yamagishi H, Miki T, Hongo F, Takaha N, Hirakawa K, Tanaka H, Stevanovic S, Frisch J, Mayer-Mokler A, Kirner A, Rammensee HG, Reinhardt C, Singh-Jasuja H (2012) Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med 18:1254–1261
50. Viaud S, Flament C, Zoubir M, Pautier P, LeCesne A, Ribrag V, Soria JC, Marty V, Vielh P, Robert C, Chaput N, Zitvogel L (2011) Cyclophosphamide induces differentiation of Th17 cells in cancer patients. Cancer Res 71:661–665
51. Noguchi M, Moriya F, Koga N, Matsueda S, Sasada T, Yamada A, Kakuma T, Itoh K (2016) A randomized phase II clinical trial of personalized peptide vaccination with metronomic low-dose cyclophosphamide in patients with metastatic castration-resistant prostate cancer. Cancer Immunol Immunother 65:151–160
52. Diaz-Montero CM, Salem ML, Nishimura MI, Garrett-Mayer E, Cole DJ, Montero AJ (2009) Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother 58:49–59
53. Luznik L, O’Donnell PV, Fuchs EJ (2012) Post-transplantation cyclophosphamide for tolerance induction in HLA-haploidentical bone marrow transplantation. Semin Oncol 39:683–693
54. Kasamon YL, Jones RJ, Gocke CD, Blackford AL, Seifter EJ, Davis-Sproul JM, Gore SD, Ambinder RF (2011) Extended follow-up of autologous bone marrow transplantation with 4-hydroperoxy-cyclophosphamide (4-HC) purging for indolent or transformed non-Hodgkin lymphomas. Biol Blood Marrow Transpl 17:365–367
55. Kanakry CG, Ganguly S, Zahurak M, Bolaños-Meade J, Thoburn C, Perkins B, Fuchs EJ, Jones RJ, Hess AD, Luznik L (2013) Aldehyde dehydrogenase expression drives human regulatory T cell resistance to posttransplantation cyclophosphamide. Sci Transl Med 5:211ra157
56. Ninomiya S, Narala N, Huye L, Yagyu S, Savoldo B, Dotti G, Heslop HE, Brenner MK, Rooney CM, Ramos CA (2015) Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs. Blood 125:3905–3916
57. Yoshikawa T, Hara T, Tsurumi H, Goto N, Hoshi M, Kitagawa J, Kanemura N, Kasahara S, Ito H, Takemura M, Saito K, Seishima M, Takami T, Moriwaki H (2010) Serum concentration of L-kynurenine predicts the clinical outcome of patients with diffuse large B-cell lymphoma treated with R-CHOP. Eur J Haematol 84:304–309
58. Ninomiya S, Hara T, Tsurumi H, Hoshi M, Kanemura N, Goto N, Kasahara S, Shimizu M, Ito H, Saito K, Hirose Y, Yamada T, Takahashi T, Seishima M, Takami T, Moriwaki H (2011) Indoleamine 2,3-dioxygenase in tumor tissue indicates prognosis in patients with diffuse large B-cell lymphoma treated with R-CHOP. Ann Hematol 90:409–416
59. Vacchelli E, Aranda F, Bloy N, Buqué A, Cremer I, Eggermont A, Fridman WH, Fucikova J, Galon J, Spisek R, Zitvogel L, Kroemer G, Galluzzi L (2015) Trial Watch—immunostimulation with cytokines in cancer therapy. Oncoimmunology 5:e1115942
60. Vacchelli E, Aranda F, Eggermont A, Sautès-Fridman C, Tartour E, Kennedy EP, Platten M, Zitvogel L, Kroemer G, Galluzzi L (2014) Trial watch: IDO inhibitors in cancer therapy. Oncoimmunology 3(10):e957994
61. Niemeyer U, Pohl J (2011) Einmalig dosierte Oxazaphosphorine zur Therapie von Krankheiten. German Patent Application DE102011085695 A1, 3rd November, 2011
62. Ninomiya S, Narala N, Huye L, Yagyu S, Savoldo B, Dotti G, Heslop HE, Brenner MK, Rooney CM, Ramos CA (2015) Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs. Blood 125(25):3905–3916
63. Dimeloe S, Frick C, Fischer M, Gubser PM, Razik L, Bantug GR, Ravon M, Langenkamp A, Hess C (2014) Human regulatory T cells lack the cyclophosphamide-extruding transporter ABCB1 and are more susceptible to cyclophosphamide-induced apoptosis. Eur J Immunol 44:3614–3620
64. Szakács G, Váradi A, Özvegy-Laczka C, Sark B (2008) The role of ABC transporters in drug absorption, distribution, metabolism, excretion and toxicity (ADME–Tox). Drug Discov Today 13:379–393
65. Zhang J, Tian Q, Yung Chan S, Chuen Li S, Zhou S, Duan W, Zhu YZ (2005) Metabolism and transport of oxazaphosphorines and the clinical implications. Drug Metab Rev. 37:611–703
66. Hsu FT, Chen TC, Chuang HY, Chang YF, Hwang JJ (2015) Enhancement of adoptive T cell transfer with single low dose pretreatment of doxorubicin or paclitaxel in mice. Oncotarget 6:44134–44150
67. Zhao J, Cao Y, Lei Z, Yang Z, Zhang B, Huang B (2010) Selective depletion of CD4+ CD25+ Foxp3+ regulatory T cells by low-dose cyclophosphamide is explained by reduced intracellular ATP levels. Cancer Res 70:4850–4858
68. Viaud S, Daillère R, Boneca IG, Lepage P, Pittet MJ, Ghiringhelli F, Trinchieri G, Goldszmid R, Zitvogel L (2014) Harnessing the intestinal microbiome for optimal therapeutic immunomodulation. Cancer Res 74:4217–4221
69. Francescone R, Hou V, Grivennikov SI (2014) Microbiome, inflammation, and cancer. Cancer J 20:181–189
70. Viaud S, Saccheri F, Mignot G, Yamazaki T, Daillère R, Hannani D, Enot DP, Pfirschke C, Engblom C, Pittet MJ, Schlitzer A, Ginhoux F, Apetoh L, Chachaty E, Woerther PL, Eberl G, Bérard M, Ecobichon C, Clermont D, Bizet C, Gaboriau-Routhiau V, Cerf-Bensussan N, Opolon P, Yessaad N, Vivier E, Ryffel B, Elson CO, Doré J, Kroemer G, Lepage P, Boneca IG, Ghiringhelli F, Zitvogel L (2013) The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science 342:971–976
71. Madondo MT, Quinn M, Plebanski M (2016) Low dose cyclophosphamide: mechanisms of T cell modulation. Cancer Treat Rev 42:3–9
72. van der Most RG, Currie AJ, Mahendran S, Prosser A, Darabi A, Robinson BW, Nowak AK, Lake RA (2009) Tumor eradication after cyclophosphamide depends on concurrent depletion of regulatory T cells: a role for cycling TNFR2-expressing effector-suppressor T cells in limiting effective chemotherapy. Cancer Immunol Immunother 58:1219–1228
73. Kohyama M, Sugahara D, Sugiyama S, Yagita H, Okumura K, Hozumi N (2004) Inducible costimulator-dependent IL-10 production by regulatory T cells specific for self-antigen. Proc Natl Acad Sci USA 101:4192–4197
74. Kanakry CG, Ganguly S, Luznik L (2015) Situational aldehyde dehydrogenase expression by regulatory T cells may explain the contextual duality of cyclophosphamide as both a pro-inflammatory and tolerogenic agent. Oncoimmunology 4:e974393
75. van der Most RG, Currie AJ, Robinson BW, Lake RA (2008) Decoding dangerous death: how cytotoxic chemotherapy invokes inflammation, immunity or nothing at all. Cell Death Differ 15:13–20
76. Galluzzi L, Buqué A, Kepp O, Zitvogel L, Kroemer G (2015) Immunological effects of conventional chemotherapy and targeted anticancer agents. Cancer Cell 28:690–714
77. Kawano M, Tanaka K, Itonaga I, Iwasaki T, Miyazaki M, Ikeda S, Tsumura H (2016) Dendritic cells combined with doxorubicin induces immunogenic cell death and exhibits antitumor effects for osteosarcoma. Oncol Lett 11:2169–2175
78. Sistigu A, Viaud S, Chaput N, Bracci L, Proietti E, Zitvogel L (2011) Immunomodulatory effects of cyclophosphamide and implementations for vaccine design. Semin Immunopathol 33:369–383
79. Patutina OA, Mironova NL, Logashenko EB, Popova NA, Nikolin VP, Vasil’ev GV, Kaledin VI, Zenkova MA, Vlasov VV (2012) Cyclophosphamide metabolite inducing apoptosis in RLS mouse lymphosarcoma cells is a substrate for P-glycoprotein. Bull Exp Biol Med 152:348–352
80. Grishanova AY, Melnikova EV, Kaledin VI, Nikolin VP, Lyakhovich VV (2005) Possible role of P-glycoprotein in cyclophosphamide resistance of transplanted mouse RLS lymphosarcoma. Bull Exp Biol Med 139:611–614
81. Brayboy LM, Oulhen N, Witmyer J, Robins J, Carson S, Wessel GM (2013) Multidrug-resistant transport activity protects oocytes from chemotherapeutic agents and changes during oocyte maturation. Fertil Steril 100:1428–1435
82. Joy MS, La M, Wang J, Bridges AS, Hu Y, Hogan SL, Frye RF, Blaisdell J, Goldstein JA, Dooley MA, Brouwer KL, Falk RJ (2012) Cyclophosphamide and 4-hydroxycyclophosphamide pharmacokinetics in patients with glomerulonephritis secondary to lupus and small vessel vasculitis. Br J Clin Pharmacol 74:445–455
83. Kim IW, Yun HY, Choi B, Han N, Kim MG, Park S, Oh JM (2013) Population pharmacokinetics analysis of cyclophosphamide with genetic effects in patients undergoing hematopoietic stem cell transplantation. Eur J Clin Pharmacol 69:1543–1551